{Reference Type}: Journal Article
{Title}: An updated safety review of the current drugs for managing ADHD in children.
{Author}: Ryst E;Childress A;
{Journal}: Expert Opin Drug Saf
{Volume}: 22
{Issue}: 11
{Year}: 2023 Jul-Dec 16
{Factor}: 4.011
{DOI}: 10.1080/14740338.2023.2271392
{Abstract}: <B>UNASSIGNED: </B>Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly prevalent condition that causes persistent problems with attention and/or hyperactivity-impulsivity and often results in significant impairment when left untreated. Medications for this disorder continue to evolve and provide new treatment options. Ongoing review of related medication safety and tolerability remains an important task for prescribers.<BR><B>UNASSIGNED: </B>This manuscript provides an updated safety review of medications used to treat ADHD in children and adolescents. PubMed and OneSearch online databases were utilized to search for literature relevant to the topic of ADHD medications and safety. Clinical trials of medications used to treat ADHD, systematic reviews and meta-analyses, and articles covering specific safety issues (adverse or unfavorable events) such as cardiovascular effects, seizures, impact on growth, depression, suicidal ideation, substance use disorders, psychosis, and tics are described.<BR><B>UNASSIGNED: </B>Available pharmacologic treatments for ADHD have favorable efficacy, safety and tolerability and allow many patients to achieve significant improvement of their symptoms. Despite the availability of multiple stimulant and non-stimulant formulations, some individuals with ADHD may not tolerate available medications or attain satisfactory improvement. To satisfy unmet clinical needs, ADHD pharmaceutical research with stimulant and nonstimulant formulations targeting dopamine, norepinephrine, and novel receptors is ongoing.